Suchergebnisse - (Person:"Wagner, Kathryn R")

PubPharm (7)

1

Lean tissue mass measurements by dual-energy X-ray absorptiometry and associations with strength and functional outcome measures in facioscapulohumeral muscular dystrophy

enthalten in: Neuromuscular disorders : NMD | 2023

von Wang, L. | Leung, D. | Wagner, K. | +20

2

Randomized phase 2 trial and open-label extension of domagrozumab in Duchenne muscular dystrophy

enthalten in: Neuromuscular disorders : NMD | 2020

von Wagner, K. | Abdel-Hamid, H. | Mah, J. | +21

ErratumIn: Neuromuscul Disord. 2021 Feb;31(2):167-168. - PMID 33451933

3

Clinical practice considerations in facioscapulohumeral muscular dystrophy Sydney, Australia, 21 September 2015

enthalten in: Neuromuscular disorders : NMD | 2016

von Tawil, R. | Mah, J. | Baker, S. | +16

4

Results of a two-year pilot study of clinical outcome measures in collagen VI- and laminin alpha2-related congenital muscular dystrophies

enthalten in: Neuromuscular disorders : NMD | 2015

von Meilleur, K. | Jain, M. | Hynan, L. | +30

5

'Double trouble' : diagnostic challenges in Duchenne muscular dystrophy in patients with an additional hereditary skeletal dysplasia

enthalten in: Neuromuscular disorders : NMD | 2013

von Donkervoort, S. | Schindler, A. | Tesi-Rocha, C. | +8

6

Reevaluating measures of disease progression in facioscapulohumeral muscular dystrophy

enthalten in: Neuromuscular disorders : NMD | 2013

von Statland, J. | McDermott, M. | Heatwole, C. | +6

7

Myostatin does not regulate cardiac hypertrophy or fibrosis

enthalten in: Neuromuscular disorders : NMD | 2007

von Cohn, R. | Liang, H. | Shetty, R. | +2

1
[1]